Lv1
76 积分 2025-09-29 加入
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
9天前
已完结
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
30天前
已完结
Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma
1个月前
已完结
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series
2个月前
已完结
Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells
3个月前
已完结
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis
3个月前
已完结
Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization
3个月前
已完结
Evaluation of an investigational wearable injector in healthy human volunteers
3个月前
已完结
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
4个月前
已完结
皖公网安备34019202002308
